| First Author | Menou A | Year | 2018 |
| Journal | Matrix Biol | Volume | 68-69 |
| Pages | 382-403 | PubMed ID | 29518524 |
| Mgi Jnum | J:265652 | Mgi Id | MGI:6196675 |
| Doi | 10.1016/j.matbio.2018.03.001 | Citation | Menou A, et al. (2018) The impaired proteases and anti-proteases balance in Idiopathic Pulmonary Fibrosis. Matrix Biol 68-69:382-403 |
| abstractText | Idiopathic Pulmonary Fibrosis (IPF) is a devastating chronic, progressive and irreversible disease that remains refractory to current therapies. Matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitors of MMPs (TIMPs), have been implicated in the development of pulmonary fibrosis since decades. Coagulation signalling deregulation, which influences several key inflammatory and fibro-proliferative responses, is also essential in IPF pathogenesis, and a growing body of evidence indicates that Protease-Activated Receptors (PARs) inhibition in IPF may be promising for future evaluation. Therefore, proteases and anti-proteases aroused great biomedical interest over the past years, owing to the identification of their potential roles in lung fibrosis. During these last decades, numerous other proteases and anti-proteases have been studied in lung fibrosis, such as matriptase, Human airway trypsin-like protease (HAT), Hepatocyte growth factor activator (HGFA)/HGFA activator inhibitor (HAI) system, Plasminogen activator inhibitor (PAI)-1, Protease nexine (PN)-1, cathepsins, calpains, and cystatin C. Herein, we provide a general overview of the proteases and anti-proteases unbalance during lung fibrogenesis and explore potential therapeutics for IPF. |
